Shattuck Labs, Inc. (STTK)
Stock Price:
$22.05 USD
1.00 (4.75%)
Updated Oct 21, 2020 4:00 PM EDT - Market closed
After-hours: $22.04 -0.01 (-0.05%) Oct 21, 4:03 PM
Key Info
| Market Cap |
881.16M |
| Revenue (ttm) |
10.76M |
| Net Income (ttm) |
-27.41M |
| Shares Out |
39.84M |
| EPS (ttm) |
-0.69 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 21, 2020 |
| Last Price |
$22.05 |
| Previous Close |
$21.05 |
| Change ($) |
1.00 |
| Change (%) |
4.75% |
| Day's Open |
21.05 |
| Day's Range |
21.05 - 22.17 |
| Day's Volume |
117,236 |
| 52-Week Range |
17.51 - 22.90 |
More Stats
| Market Cap |
881.16M |
| Enterprise Value |
733.63M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
39.84M |
| Float |
28.43M |
| EPS (basic) |
n/a |
| EPS (diluted) |
-0.69 |
| FCF / Share |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
n/a |
| Short Ratio |
n/a |
| Short % of Float |
n/a |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
81.88 |
| PB Ratio |
6.71 |
| Revenue |
10.76M |
| Operating Income |
n/a |
| Net Income |
-27.41M |
| Free Cash Flow |
n/a |
| Net Cash |
147.53M |
| Net Cash / Share |
3.69 |
| Gross Margin |
-179.62% |
| Operating Margin |
n/a |
| Profit Margin |
-254.69% |
| FCF Margin |
n/a |
| ROA |
n/a |
| ROE |
n/a |
| ROIC |
n/a |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (0)
| Buy |
0 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
*No analysts have provided price targets for this stock.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 |
|---|
| Revenue | 9.89 | 22.44 |
| Revenue Growth | -55.94% | - |
| Gross Profit | 9.89 | 22.44 |
| Operating Income | -25.07 | -6.15 |
| Net Income | -23.98 | -7.39 |
| Shares Outstanding | 7.56 | 7.41 |
| Earnings Per Share | -3.17 | -1.00 |
| Operating Cash Flow | -20.98 | -6.90 |
| Capital Expenditures | -0.47 | -1.18 |
| Free Cash Flow | -21.45 | -8.08 |
| Cash & Equivalents | 39.09 | 60.38 |
| Net Cash / Debt | 39.09 | 60.38 |
| Assets | 44.97 | 68.16 |
| Liabilities | 30.45 | 30.18 |
| Book Value | -34.55 | -11.08 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Shattuck Labs, Inc. |
| Country |
United States |
| Employees |
45 |
| CEO |
Taylor H. Schreiber |
Stock Information
| Ticker Symbol |
STTK |
| Stock Exchange |
NASDAQ |
| Sector |
Health Technology |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: STTK |
| IPO Date |
October 9, 2020 |
Description
Shattuck Labs, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian cancer. It also holds a collaboration agreement with Takeda Pharmaceuticals to develop SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was founded in 2016 and is headquartered in Austin, Texas.